Abstract
A gene-directed enzyme pro-drug therapy (GDEPT) based on purine nucleoside phosphorylase (PNP), that converts the prodrug, fludarabine to 2-fluoroadenine, has been described, but studies are limited compared with other GDEPTs. We investigated the in vitro and in vivo efficacies of PNP-GDEPT for treating androgen-independent (AI) prostate cancer. The PNP gene controlled by Rous sarcoma virus (RSV) constitutive promoter was delivered using a recombinant ovine adenovirus vector (OAdV220) that uses a different receptor from human adenovirus type 5. In vitro, OAdV220 provided increased transgene expression over a comparable human Ad5 vector in infected AI, murine RM1 prostate cancer cells. Subsequent in vivo testing was therefore confined to OAdV220. Transduction of RM1 cells with OAdV220 before implantation in immunocompetent mice dramatically inhibited subcutaneous (s.c.) tumor growth when fludarabine phosphate was administered systemically and increased mouse survival in a dose-dependent manner. In tumor-bearing C57BL/6 mice, a single intratumoral injection of OAdV220 produced detectable PNP activity for at least 6 days and with prodrug, retarded the growth of aggressive RM1 s.c. tumors by 35% at day 14. There was a consistent trend to reduction of pre-established intraprostatic RM1 tumors. A similar regimen induced significant therapeutic efficacy in human PC3 xenografts. Thus, ovine adenovirus-mediated GDEPT using the PNP system was effective in vivo against AI prostate cancers, the aggressive murine RM1, and the human PC3 lines. Methods that improve viral dissemination and stimulate the immune system in vivo may further improve efficacy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Parker SH, Tong T, Bolden S, Wingo PA . Cancer statistics 1996 CA Cancer J Clin 1996 46: 5–27
Landis SH . Murray T, Bolden S, Wingo PA. Cancer statistics, 1998 CA Cancer J Clin 1998 48: 6–29
Alexianu M, Weiss GH . Radical prostatectomy versus brachytherapy for early-stage prostate cancer J Endourol 2000 14: 325–328
Dahm P et al. Outcome profiles of locoregional disease after radical prostatectomy and radiotherapy World J Urol 2000 18: 173–178
Denis L, Murphy GP . Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer Cancer (Phila) 1993 72: 3888–3895
Hrouda D, Dalgleish AG . Gene therapy for prostate cancer Gene Therapy 1996 3: 845–852
Russell PJ et al. Prostate cancer gene therapy Australasian Biotechnology 1998 8: 99–106
Palapattu GS, Naitoh J, Belldegrun AS . Gene therapy for prostate cancer. New perspectives on an old problem Urologic Clinics Nth America 1999 26: 353–363
Vieweg J et al. Immunotherapy of prostate cancer in the Dunning rat model – use of cytokine gene modified tumor vaccines Cancer Res 1994 54: 1760–1765
Ko S-C et al. Molecular therapy with recombinant p53 adenovirus to an androgen-independent, metastatic human prostate cancer model Hum Gene Ther 1996 7: 1683–1691
Miyake H, Tolcher A, Gleave ME . Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model Cancer Res 1999 59: 4030–4034
Chen S-HC et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo Proc Natl Acad Sci USA 1995 92: 2577–2581
Eastham JA et al. Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models Hum Gene Ther 1996 7: 515–523
Greenberg N et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice Mol Endocrinol 1994 8: 230–239
Kasper A et al. Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene J Biol Chem 1994 269: 31763–31769
Hughes BW et al. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene Cancer Res 1995 55: 3339–3345
Brookes DE et al. Relative activity and specificity of promoters from prostate-expressed genes Prostate 1998 35: 8–26
Martiniello-Wilks R et al. In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-prodrug systems delivered by identical adenovirus vectors Hum Gene Ther 1998 9: 1617–1626
Watt F et al. A transcriptional enhancer of the prostate-specific membrane antigen gene Genomics 2001 73: 243–254
Rodriguez R et al. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells Cancer Res 1997 57: 2559–2563
Douglas JT et al. Targeted gene delivery by tropism-modified adenoviral vectors Nat Biotechnol 1996 14: 1574–1578
Watkins SJ, Mesyanzhinov VV, Kurochkina LP, Hawkins RE . The ‘adenobody’ approach to viral targeting: specific and enhanced adenoviral gene delivery Gene Therapy 1997 4: 1004–1012
Reynolds PN, Dimitriev I, Curiel DT . Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector Gene Therapy 1999 6: 1336–1339
Romanczuk H et al. Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice Hum Gene Ther 1999 10: 2615–2626
Hermann JR et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial Hum Gene Ther 1999 10: 1239–1249
Berges RR et al. Implication of cell kinetic changes during progression of human prostatic cancer Clin Cancer Res 1995 1: 473–480
Parker WB et al. In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase Hum Gene Ther 1997 8: 1637–1644
Parker WB et al. Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells Biochem Pharmacol 1998 55: 1673–1681
Sorscher EJ et al. Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines Gene Therapy 1994 1: 233–238
Lockett LJ, Molloy PL, Russell PJ, Both GW . Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors Clin Cancer Res 1997 3: 2075–2080
Bramson JL, Hitt M, Gauldie J, Graham FL . Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination Gene Therapy 1997 4: 1069–1076
Ilan Y et al. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses Hepatology 1998 27: 1368–1376
Benihoud K, Yeh P, Perricaudet M . Adenovirus vectors for gene delivery Curr Opin Biotechnol 1999 10: 440–447
Bergelson JM et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5 Science 1997 275: 1320–1323
Tomko RP, Xu RL, Philipson L . HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses Proc Natl Acad Sci USA 1997 94: 3352–3356
Nemerow GR . Cell receptors involved in adenovirus entry Virology 2000 274: 1–4
Hofmann C et al. Ovine adenovirus vectors overcome pre-existing humoral immunity against human adenoviruses in vivo J Virol 1999 73: 6930–6936
Xu ZZ, Both GW . Altered tropism of an ovine adenovirus carrying the fiber protein cell binding domain of human adenovirus type 5 Virology 1997 248: 156–163
Khatri A, Xu ZZ, Both GW . Gene expression by atypical recombinant ovine adenovirus vectors during abortive infection of human and animal cells in vitro Virology 1997 239: 226–237
Thompson TC, Southgate J, Kitchener G, Land H . Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted model Cell 1989 5: 917–930
Hall SJ et al. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer Int J Cancer 1997 70: 183–187
Hall SJ et al. Induction of potent antitumor natural killer cell activity by herpes simplex virus thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer Cancer Res 1998 58: 3221–3225
Yamamoto T, Jay G, Pastan I . Unusual features in the nucleotide sequence of a cDNA clone derived from the common region of avian sarcoma virus messenger RNA Proc Natl Acad Sci USA 1980 77: 176–180
Loser P et al. Ovine adenovirus vectors promote efficient gene delivery in vivo Gene Ther Mol Biol 1999 4: 33–43
Secrist JA et al. Gene therapy of cancer: activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase Nucleosides Nucleotides 1999 18: 745–757
Xu ZZ et al. An ovine adenovirus vector lacks transforming ability in cells that are transformed by AD5 E1A/B sequences Virology 2000 270: 162–172
Plunkett WF et al. ludarabine: pharmacokinetics, mechanisms of action and rationales for combination therapies Semin Oncol 1993 20: 2–12
Hutton JJ et al. Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5’-monophosphate (NSC 312887), a new purine antimetabolite Cancer Res 1984 44: 4183–4186
Snyder FF, Lukey T . Kinetic considerations for the regulation of adenosine and deoxyadenosine metabolism in mouse and human tissues based on a thymocyte model Biochem Biophys Acta 1982 696: 299–307
Carson DA, Kaye J, Wasson DB . Differences in deoxyadenosine metabolism in human and mouse lymphocytes J Immunol 1980 124: 8–12
Vrati S et al. Construction and transfection of ovine adenovirus genomic clones to rescue modified viruses Virology 1996 220: 200–203
Boyle DB et al. Characterisation of Australian ovine adenovirus isolates Vet Microbiol 1994 41: 281–291
Mittereder N, March KL, Trapnell BC . Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy J Virol 1996 70: 7498–7509
Anderson-McKay JE, Both GW, Simpson G . Regio- and stereo-selective synthesis of 6-methyl-9-(2-deoxy-β-D-erythro-pentofuranosyl)purine Nucleotides Nucleosides 1996 15: 1307–1313
Russell PJ et al. Bladder cancer xenografts: a model of tumor cell heterogeneity Cancer Res 1986 46: 2035–2040
Acknowledgements
The authors thank Professor Peter Russell, Department of Anatomical Pathology, Royal Prince Alfred Hospital, Sydney for conducting histological analyses. Funding for this study was provided, in part, by FH Faulding and Co Limited.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Voeks, D., Martiniello-Wilks, R., Madden, V. et al. Gene therapy for prostate cancer delivered by ovine adenovirus and mediated by purine nucleoside phosphorylase and fludarabine in mouse models. Gene Ther 9, 759–768 (2002). https://doi.org/10.1038/sj.gt.3301698
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301698
Keywords
This article is cited by
-
The use of Trichomonas vaginalis purine nucleoside phosphorylase to activate fludarabine in the treatment of solid tumors
Cancer Chemotherapy and Pharmacology (2020)
-
Aromatic 19F-13C TROSY: a background-free approach to probe biomolecular structure, function, and dynamics
Nature Methods (2019)
-
Targeted enzyme prodrug therapy for metastatic prostate cancer – a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase
Journal of Biomedical Science (2014)
-
Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: A tangible union against chemoresistant cancer
BMC Cancer (2011)
-
Enhanced efficiency of prodrug activation therapy by tumor-selective replicating retrovirus vectors armed with the Escherichia coli purine nucleoside phosphorylase gene
Cancer Gene Therapy (2010)